Cancer Drug CADD522 Shows Promise for Post-Menopausal Osteoporosis

University of East Anglia Researchers Target RUNX2 Protein

According to Dr Darrell Green, Lead Researcher at UEA’s Norwich Medical School, targeting this protein yielded unexpected benefits for bone health and metabolism in post-menopausal mice following an eight-week treatment period.

The team observed that treated mice maintained greater bone volume and better preservation of the delicate honeycomb-like structures inside bones that help them withstand stress compared to untreated control groups.

Stimulating Bone Formation Versus Suppressing Bone Breakdown

Menopause can disrupt this balance, accelerating bone loss and increasing fracture risk, particularly in the hip, spine and wrist, as oestrogen levels fall. Many existing osteoporosis treatments work by slowing bone breakdown.

Unexpected Effects on Body Fat and Metabolism in Preclinical Tests

Beyond skeletal improvements, the study revealed that CADD522 appeared to affect metabolism as well as bone. Mice receiving CADD522 weighed less than their untreated counterparts despite eating the same amount of food, according to the university’s findings.

Brain tissue examinations further showed that the drug appeared to reverse several menopause-related changes in fatty acids.

Next Steps for Clinical Trials and Human Testing

The biggest question is whether the findings will translate to humans.

Frequently Asked Questions

What is CADD522?

CADD522 is an experimental compound originally developed to block RUNX2, a protein involved in the growth and spread of several cancers. Recent research shows it may also stimulate bone formation and improve fat metabolism.

How does menopause affect bone health?

Oestrogen helps regulate bone remodelling. When oestrogen levels fall during and after menopause, bone breakdown can accelerate, making bones weaker, less dense, and more vulnerable to fractures.

Has CADD522 been tested in humans?

Clinical trials are necessary to determine safety and efficacy in humans.